Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony chłoniak z dużych komórek B (DLBCL), chłoniak pierwotnie śródpiersiowy, wysoko-złośliwy chłoniak z komórek B lub chłoniak z komórek B powstały z wolno rosnących chłoniaków
- •Mierzalne zmiany nowotworowe o wielkości co najmniej 15 mm widoczne w badaniu PET, CT lub MRI (zrobione w ciągu miesiąca przed badaniem)
- •Niepowodzenie wcześniejszego leczenia pierwszej linii i kwalifikacja do terapii CAR-T (axicabtagene ciloleucel, lisocabtagene maraleucel lub tisagenlecleucel)
- •Wiek co najmniej 18 lat
- •Zdolność do zrozumienia i podpisania świadomej zgody
- •Wcześniejsze leczenie lekami anty-CD20
- •Dobry stan ogólny pacjenta (karność 0-1, w wyjątkowych przypadkach 2 jeśli wynika z choroby)
- •Prawidłowa funkcja nerek, wątroby, płuc i serca oraz liczba krwinek w normie (lub bliska normie)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Mengyang Di, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.